Status and phase
Conditions
Treatments
About
Repetitive levosimendan infusions for patients with advanced chronic heart failure (LeoDOR) A randomised, double-blind, placebo-controlled multicentre study with parallel group design.
Mortality and rehospitalisation rates are high in the vulnerable phase following heart failure hospitalisation. Previous studies suggest that these events can be reduced by repeat infusions of levosimendan in patients with advanced heart failure.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
264 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Kathrin Becker, PhD.; Sabine Embacher-Aichhorn
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal